Kyle Alliman, MD
Ophthalmology · West Des Moines, IANPI 1437360351
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.5%), ownership interests and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by US Retina LLC at 32.0% of the total.
Across 87 payments — averaging $86.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$2K
- Onmark, Inc.$1K
- Genentech, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$906
- Alcon$336
- Apellis Pharmaceuticals, Inc.$334
- plus $1K from 9 others
Across 15 payments — averaging $6148.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$41K
- Novartis$35K
- Astellas Pharma Global Development$12K
- Alcon Research LLC$5K
What the payments were for
- Travel & lodging$1,31718%
- Food & beverage$3,78950%
- Ownership interest$2,40332%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 5 | $2,403 |
| Onmark, Inc. | 9 | $1,300 |
| Genentech, Inc. | 5 | $1,094 |
| Regeneron Healthcare Solutions, Inc. | 29 | $906 |
| Alcon | 3 | $336 |
| Apellis Pharmaceuticals, Inc. | 15 | $334 |
| Dutch Ophthalmic, USA | 2 | $279 |
| Astellas Pharma US Inc | 6 | $224 |
| US Oncology Corporate, Inc. | 1 | $222 |
| AbbVie(2 entities) | 2 | $139 |
| Biogen | 2 | $122 |
| Bausch & Lomb Americas Inc. | 5 | $91 |
| ANI Pharmaceuticals, Inc. | 1 | $26 |
| Ocular Therapeutix, Inc. | 1 | $21 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$905
- EVA, combined machine$279
- TISSUEBLUE$279
- Centurion$170
- NGENUITY$150
- EYLEA HD$149
- Syfovre$128
- OZURDEX$125
- VUITY$125
- VABYSMO$106
- Izervay$103
How this compares
$7,509 in reported general payments places this provider in the 85th percentile of 172 ophthalmology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 29 | $14,591 |
| Prednisolone Acetate | 303 | $12,592 |
| CombiganBrimonidine Tartrate/Timolol | 19 | $6,199 |
| Difluprednate | 42 | $5,712 |
| Brinzolamide | 21 | $4,101 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 16 | $2,956 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 11 | $2,191 |
| MoxifloxacinMoxifloxacin Hcl | 82 | $1,825 |
| Latanoprost | 133 | $1,366 |
| Timolol Maleate | 64 | $532 |
| Dorzolamide Hcl | 37 | $442 |
| Atropine Sulfate | 12 | $429 |
| Brimonidine Tartrate | 27 | $387 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 32 | $323 |
| ErythromycinErythromycin Base | 25 | $245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan | $139 | $20,79048 claims |
| AlconSimbrinza | $336 | $2,19111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 172 ophthalmology providers in Iowa.
Other ophthalmology in West Des Moines
- Jared NielsenWest Des Moines$117K
- Matthew RauenWest Des Moines$108K
- Frederick BlodiWest Des Moines$6K
- Valerie KounkelWest Des Moines$4K
- George ClavennaWest Des Moines$4K
- Andrew SteffensmeierWest Des Moines$3K
- Matthew RaeckerWest Des Moines$3K
- Mohamed HassanWest Des Moines$3K
- Steven JohnsonWest Des Moines$3K
- David SaggauWest Des Moines$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.